CIK 0001650648 · Non-accelerated filer<br>Smaller reporting company
4D Molecular Therapeutics, Inc.
Sign in to watch- Ticker
- FDMT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473506994
- Phone
- 5105052680
- Business address
- 5858 HORTON STREET #455, EMERYVILLE, CA, 94608
- Former names
- 4D Molecular Therapeutics Inc., 4D Molecular Therapeutics Inc
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Legal Officer sold 1,750 shares at an average $25.45 ($44,541)
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
- 4 Planned sale Chief Legal Officer sold 1,750 shares at $25.74 ($45,045)
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Planned sale Chief Legal Officer sold 8,153 shares at $31.78 ($259,102)
- 144 Insider Sale of Securities
- 4 Planned sale Chief Legal Officer sold 5,833 shares at $35.04 ($204,410)
- 4 Planned sale Chief Legal Officer sold 1,750 shares at $31.27 ($54,723)
- 4 Planned sale Chief Legal Officer sold 1,909 shares at $30.00 ($57,270)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Planned sale Chief Legal Officer sold 1,750 shares at $27.67 ($48,423)
Page 10 of 23 · 442 filings